Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Biodivers ; 20(3): e202200973, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36691991

ABSTRACT

Methoxy group enriched eight coumarin-chalcone hybrid derivatives were synthesized. Antimicrobial/ antiproliferative activities were tested against eight human pathogenic microorganisms and four cancer cell lines (AGS, HepG2, MCF-7 and PC-3), respectively. Antimicrobial results showed that most of the compounds were almost more active than used standard antibiotics. Cytotoxicity results showed that 2,3,4-trimethoxyphenyl and thiophene containing structures have promising antiproliferative effects against AGS gastric cell lines with ∼5 µg/ml IC50 values. At the same time, 2,4-dimethoxyphenyl bearing derivative exhibited the lowest IC50 values against HepG2 (∼10 µg/ml) and PC-3 (∼5 µg/ml) cell lines. Particularly, the cell viabilities of MCF-7 cell lines were remarkably inhibited by all the compounds with lower IC50 values. Therefore, molecular docking studies between hybrid ligands and quinone reductase-2 enzyme (regulates in MCF-7 cancer cells) were performed. The results demonstrated that all the derivatives can smoothly interact with interested enzyme in agreement with the experimental results. Finally, ADME parameters were studied to reveal drug-likeness potentials of the coumarin-chalcone hybrids.


Subject(s)
Anti-Infective Agents , Antineoplastic Agents , Chalcone , Chalcones , Humans , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Cell Proliferation , Chalcone/pharmacology , Chalcone/chemistry , Chalcones/pharmacology , Chalcones/chemistry , Coumarins/pharmacology , Coumarins/chemistry , Drug Screening Assays, Antitumor , MCF-7 Cells , Molecular Docking Simulation , Molecular Structure , Structure-Activity Relationship
2.
Exp Biol Med (Maywood) ; 246(3): 354-367, 2021 02.
Article in English | MEDLINE | ID: mdl-32954815

ABSTRACT

Bladder cancer is a disease that negatively affects patients' quality of life, but treatment options have remained unchanged for a long time. Although promising results have been achieved with current bladder cancer treatments, cancer recurrence, progression, and therapy resistance are the most severe problems preventing the efficiency of bladder cancer treatments. Autophagy refers to an evolutionarily conserved catabolic process in which proteins, damaged organelles, and cytoplasmic components are degraded by lysosomal enzymes. Autophagy regulates the therapeutic response to the chemotherapy drugs, thus determining the effect of therapy on cancer cells. Autophagy is a stress-induced cell survival mechanism and its excessive stimulation can cause resistance of tumor cells to therapeutic agents. Depending on the conditions, an increase in autophagy may cause treatment resistance or autophagic cell death, and it is related to important anti-cancer mechanisms, such as apoptosis. Therefore, understanding the roles of autophagy under different conditions is important for designing effective anti-cancer agents. The dual role of autophagy in cancer has attracted considerable attention in respect of bladder cancer treatment. In this review, we summarize the basic characteristics of autophagy, including its mechanisms, regulation, and functions, and we present examples from current studies concerning the dual role of autophagy in bladder cancer progression and therapy.


Subject(s)
Antineoplastic Agents/metabolism , Antineoplastic Agents/therapeutic use , Autophagy/physiology , Drug Resistance, Neoplasm/physiology , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathology , Apoptosis/physiology , Autophagy/drug effects , Cell Survival , Endoplasmic Reticulum Stress/physiology , Humans , Oxidative Stress/physiology , Signal Transduction/drug effects
3.
Exp Biol Med (Maywood) ; 245(9): 805-814, 2020 05.
Article in English | MEDLINE | ID: mdl-32252554

ABSTRACT

IMPACT STATEMENT: Alternative agents that will increase the effectiveness of cisplatin, which are widely used in the advanced stage and metastatic bladder cancer, are being investigated. In previous studies, Cucurbitacin B (CuB), which is a natural compound from the Cucurbitaceae family has been shown to inhibit the proliferation of tumor cells and create synergistic effects with cisplatin. In this study, we investigated the synergistic effect of CuB with cisplatin for the first time in bladder cancer in vitro and in vivo models. Our findings showed that CuB treatment with cisplatin reduced cell proliferation, and reduced tumor development through activating apoptosis and autophagy via PI3K/AKT/mTOR signaling pathway. Our results showed that CuB may be a new agent that can support conventional treatment in bladder cancer. Our study is important in terms of enlightening new pathways and developing new treatment methods in the treatment of bladder cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cisplatin/pharmacology , Triterpenes/pharmacology , Urinary Bladder Neoplasms/pathology , Animals , Apoptosis/drug effects , Autophagy/drug effects , Cell Proliferation/drug effects , Disease Models, Animal , Drug Synergism , Mice , Mice, Inbred C57BL , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...